CNBC Investing Club

Cramer's Investing Club Stock Profile: Drugmaker Abbvie deserves a lot more love from the market

A sign stands outside a Abbvie facility in Cambridge, Massachusetts, May 20, 2021.
Brian Snyder | Reuters

Abbvie (ABBV) is a leading biopharmaceutical firm that's transformed itself from a mostly one-drug company to a diversified business after the 2020 acquisition of Allergan.

More In CNBC Investing Club

CNBC Investing ClubJune 27, 2022: Cramer likes these stocks on looming earnings calls
31 min ago
CNBC Investing ClubWhat Cramer is watching Monday — SEC chair speaks, Pioneer CEO says no to Biden
2 hours ago
CNBC Investing ClubInvesting Club: The week in review, the week ahead — June 24, 2022